Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc is a biotechnology company which develops and commercializes biopharmaceutical products to address central nervous system disorders. It aims to discover small molecule drugs to address Parkinson's, Alzheimer's and schizophrenia.
IPO Date: June 1, 2004
Sector: Healthcare
Industry: Biotech
Market Cap: $3.68B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.44 | 2.68%
Avg Daily Range (30 D): $0.35 | 1.59%
Avg Daily Range (90 D): $0.36 | 1.99%
Institutional Daily Volume
Avg Daily Volume: 1.2M
Avg Daily Volume (30 D): 1.38M
Avg Daily Volume (90 D): 1.56M
Trade Size
Avg Trade Size (Sh.): 130
Avg Trade Size (Sh.) (30 D): 68
Avg Trade Size (Sh.) (90 D): 66
Institutional Trades
Total Inst.Trades: 9,743
Avg Inst. Trade: $2.26M
Avg Inst. Trade (30 D): $3.68M
Avg Inst. Trade (90 D): $3.64M
Avg Inst. Trade Volume: .09M
Avg Inst. Trades (Per Day): 3
Market Closing Trades
Avg Closing Trade: $4.08M
Avg Closing Trade (30 D): $7.53M
Avg Closing Trade (90 D): $6.47M
Avg Closing Volume: 169.98K
   
News
Apr 22, 2025 @ 5:00 PM
Parkinson’s Disease Therapeutic Domain Proj...
Source: Delveinsight
Feb 11, 2025 @ 8:48 AM
Neuroregeneration Therapy Market to Surpass USD 64...
Source: Transparency Market Research
Jun 27, 2024 @ 12:41 PM
This Vertex Pharmaceuticals Analyst Begins Coverag...
Source: Avi Kapoor
Jun 24, 2024 @ 10:49 AM
Alnylam (ALNY) Soars 5.3%: Is Further Upside Left ...
Source: Zacks Equity Research
Jun 7, 2024 @ 3:30 PM
Acadia (ACAD) Up 0.6% Since Last Earnings Report: ...
Source: Zacks Equity Research
Financials
  TTM Q1 2025 Q3 2024
Basic EPS $.11 $.2
Diluted EPS $.11 $.2
Revenue $ $ 244.32M $ 250.4M
Gross Profit $ $ 223.93M $ 231.54M
Net Income / Loss $ $ 18.99M $ 32.77M
Operating Income / Loss $ $ 19.29M $ 31.64M
Cost of Revenue $ $ 20.39M $ 18.86M
Net Cash Flow $ $ -101.89M $ -18.94M
PE Ratio